The label expansion for ibrutinib with an oral suspension formulation has been approved by the FDA in all current indications including Waldenström macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, and chronic graft-versus-host disease.
New research out of VCU Massey Comprehensive Cancer Center and VCU Health Pauley Heart Center indicates that survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event — including heart failure, heart attack or stroke — than the general public.
An expert discussed how the benefits of mindfulness in patients with cancer can also be applied to oncology nurses.
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with lisocabtagene maraleucel experienced durable responses.
Oncology nurses can advocate for patients with cholangiocarcinoma to participate in on-going clinical trials with tinengotinib.
The antifungal prophylaxis azoles did not impact the safety and efficacy of ruxolitinib in patients with graft-vs-host disease.
During a Community Case Forum, Tiffany Bostwick, P.A., discussed how immunotherapy for advanced endometrial cancer has contributed to improved results compared with the previous standard of care.
Patients with GVHD treated with ruxolitinib plus belumosudil experienced an overall response rate of 55%, which may suggest an interaction between inflammatory pathways.
The FDA is currently reviewing a BLA that seeks the approval of datopotamab deruxtecan as a therapeutic option for pretreated nonsquamous non–small cell lung cancer.
Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.
It may be feasible to use brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.
Liso-cel may be an effective treatment option for relapsed/refractory mantle cell lymphoma, including those with high-risk features who have limited treatment options.
Two experts commented on ways oncology nurses can learn more about administering TIL therapy and how they can play a supportive role for patients receiving the treatment.
Lurbinectedin confers greater activity with a superior safety profile when compared with topotecan in a subset of patients with small cell lung cancer.
Oncology nurses can assist patients in understanding the significance of KRAS mutation testing and its treatment implications.
A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.
Wearable technology can track hand hygiene protocol adherence, making wards more aware of their hand washing and sanitizing rates on a weekly basis.
Treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer, as shown in a patient reported outcome analysis of the phase 3 OlympiA trial.
Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.
All prespecified patient subgroups with metastatic urothelial cancer showed a clinical benefit with sacituzumab govitecan plus pembrolizumab in cohort 3 of the phase 2 TROPHY-U-01 trial.
The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.
The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.
The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.
Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.
A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.
The FDA granted an orphan drug designation to soquelitinib for potential use in T-cell lymphoma.
Tepotinib has received a traditional approval from the FDA for metastatic NSCLC with MET exon 14 skipping alterations, updating the previous accelerated approval from 2021.
Dawn Landolph, RN, BSN, OCN, MPA, provides an in-depth look at adagrasib for the treatment of patients with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer in a downloadable reference sheet.
Patients with recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype did not derive a survival benefit with trabectedin when compared with chemotherapy.
